Lexeo Therapeutics, Inc. Common Stock (LXEO) NASDAQ
6.44
+0.13(+2.06%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
6.44
+0.13(+2.06%)
Currency In USD
| Previous Close | 6.31 |
| Open | 6.47 |
| Day High | 6.61 |
| Day Low | 6.22 |
| 52-Week High | 10.99 |
| 52-Week Low | 1.75 |
| Volume | 1.02M |
| Average Volume | 1.07M |
| Market Cap | 477.12M |
| PE | -3.46 |
| EPS | -1.86 |
| Moving Average 50 Days | 6.61 |
| Moving Average 200 Days | 6.88 |
| Change | 0.13 |
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference
GlobeNewswire Inc.
Mar 03, 2026 12:30 PM GMT
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February
GlobeNewswire Inc.
Feb 05, 2026 12:30 PM GMT
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will par
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
GlobeNewswire Inc.
Jan 27, 2026 12:30 PM GMT
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a series of key senior leadership a